| TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
|
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
|
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| T cell dysfunctions in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Genetics of Progression From MDS to Secondary Leukemia |
|
Blood |
Myelodysplastic Syndromes (MDS) |
